Baseline serum interleukin-6 predicts cardiovascular events in incident peritoneal dialysis patients

Peritoneal Dialysis International

Volumn 35, Issue 1, 2015, Pages 35-42

  Cho, Yeoungjee ^a,b,c   Johnson, David W ^a,b,c   Vesey, David A ^a,b,c   Hawley, Carmel M ^a,b,c   Pascoe, Elaine M ^b   Clarke, Margaret ^d   Topley, Nicholas ^e  

^a PRINCESS ALEXANDRA HOSPITAL   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c TRANSLATIONAL RESEARCH INSTITUTE   (Australia)

^d Fresenius Medical Care   (Australia)

^e CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Biocompatibility; Cardiovascular events; Glucose degradation products; Interleukin 6; Mortality

Indexed keywords

ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; GLUCOSE DEGRADATION PRODUCT; HEMOGLOBIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; SERUM ALBUMIN; BIOLOGICAL MARKER;

ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DIABETES MELLITUS; ELECTROIMMUNOASSAY; ETHNICITY; FEMALE; GLOMERULUS FILTRATION RATE; HEART MUSCLE ISCHEMIA; HEART VENTRICLE ARRHYTHMIA; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERITONEAL DIALYSIS; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; URINE VOLUME; ADVERSE EFFECTS; AGED; BLOOD; CARDIOVASCULAR DISEASES; COHORT ANALYSIS; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; NONPARAMETRIC TEST; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS; RETROSPECTIVE STUDY; STATISTICAL MODEL; SURVIVAL RATE;

ADULT; AGED; BIOMARKERS; CARDIOVASCULAR DISEASES; COHORT STUDIES; FEMALE; HUMANS; INTERLEUKIN-6; KIDNEY FAILURE, CHRONIC; LINEAR MODELS; MALE; MIDDLE AGED; PERITONEAL DIALYSIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84926645220     PISSN: 08968608     EISSN: 17184304     Source Type: Journal    
DOI: 10.3747/pdi.2013.00272     Document Type: Article

References (29)

1. Johnson DW, Dent H, Hawley CM, McDonald SP, Rosman JB, Brown FG, et al. Association of dialysis modality and cardiovascular mortality in incident dialysis patients. Clin J Am Soc Nephrol 2009; 4:1620–8.
2. Becker AE, de Boer OJ, van Der Wal AC. The role of inflammation and infection in coronary artery disease. Annu Rev Med 2001; 52:289–97.
3. Williams JD, Craig KJ, Topley N, Von Ruhland C, Fallon M, Newman GR, et al. Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 2002; 13:470–9.
4. Ayuzawa N, Ishibashi Y, Takazawa Y, Kume H, Fujita T. Peritoneal morphology after long-term peritoneal dialysis with biocompatible fluid: recent clinical practice in Japan. Perit Dial Int 2012; 32:159–67.
5. Mortier S, Faict D, Schalkwijk CG, Lameire NH, De Vriese AS. Long-term exposure to new peritoneal dialysis solutions: effects on the peritoneal membrane. Kidney Int 2004; 66:1257–65.
6. Mortier S, Lameire NH, De Vriese AS. The effects of peritoneal dialysis solutions on peritoneal host defense. Perit Dial Int 2004; 24:123–38.
7. Johnson DW, Brown FG, Clarke M, Boudville N, Elias TJ, Foo MW, et al. The effects of biocompatible compared with standard peritoneal dialysis solutions on peritonitis microbiology, treatment, and outcomes: the balANZ trial. Perit Dial Int 2012; 32:497–506.
8. Justo P, Sanz AB, Egido J, Ortiz A. 3,4-Dideoxyglucosone-3-ene induces apoptosis in renal tubular epithelial cells. Diabetes 2005; 54:2424–9.
9. Hurst SM, Wilkinson TS, McLoughlin RM, Jones S, Horiuchi S, Yamamoto N, et al. IL-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity 2001; 14:705–14.
10. Humphries SE, Luong LA, Ogg MS, Hawe E, Miller GJ. The interleukin-6-174 G/C promoter polymorphism is associated with risk of coronary heart disease and systolic blood pressure in healthy men. Eur Heart J 2001; 22:2243–52.
11. Verduijn M, Marechal C, Coester AM, Sampimon DE, Boeschoten EW, Dekker FW, et al. The –174G/C variant of IL6 as risk factor for mortality and technique failure in a large cohort of peritoneal dialysis patients. Nephrol Dial Transplant 2012; 27:3516–23.
12. Liu Y, Berthier-Schaad Y, Fallin MD, Fink NE, Tracy RP, Klag MJ, et al. IL-6 haplotypes, inflammation, and risk for cardiovascular disease in a multiethnic dialysis cohort. JAm Soc Nephrol 2006; 17:863–70.
13. Zoccali C, Tripepi G, Mallamaci F. Dissecting inflammation in ESRD: do cytokines and C-reactive protein have a complementary prognostic value for mortality in dialysis patients? J Am Soc Nephrol 2006; 17(Suppl 3):S169–73.
14. Johnson DW, Brown FG, Clarke M, Boudville N, Elias TJ, Foo MW, et al. Effects of biocompatible versus standard fluid on peritoneal dialysis outcomes. J Am Soc Nephrol 2012; 23:1097–107.
15. Johnson DW, Clarke M, Wilson V, Woods F, Brown FG. Rationale and design of the balANZ trial: a randomised controlled trial of low GDP, neutral pH versus standard peritoneal dialysis solution for the preservation of residual renal function. BMC Nephrol 2010; 11:25.
16. Johnson DW, Brown FG, Clarke M, Boudville N, Elias TJ, Foo MW, et al. The effect of low glucose degradation product, neutral pH versus standard peritoneal dialysis solutions on peritoneal membrane function: the balANZ trial. Nephrol Dial Transplant 2012; 27:4445–53.
17. Pecoits-Filho R, Carvalho MJ, Stenvinkel P, Lindholm B, Heimbürger O. Systemic and intraperitoneal interleukin-6 system during the first year of peritoneal dialysis. Perit Dial Int 2006; 26:53–63.
18. Lambie M, Chess J, Donovan KL, Kim YL, Do JY, Lee HB, et al. Independent effects of systemic and peritoneal inflammation on peritoneal dialysis survival. J Am Soc Nephrol 2013; 24:2071–80.
19. Cho JH, Hur IK, Kim CD, Park SH, Ryu HM, Yook JM, et al. Impact of systemic and local peritoneal inflammation on peritoneal solute transport rate in new peritoneal dialysis patients: a 1-year prospective study. Nephrol Dial Transplant 2010; 25:1964–73.
20. Szeto CC, Chow KM, Lam CW, Leung CB, Kwan BC, Chung KY, et al. Clinical biocompatibility of a neutral peritoneal dialysis solution with minimal glucose-degradation products—a 1-year randomized control trial. Nephrol Dial Transplant 2007; 22:552–9.
21. Weiss L, Stegmayr B, Malmsten G, Tejde M, Hadimeri H, Siegert CE, et al. Biocompatibility and tolerability of a purely bicarbonate-buffered peritoneal dialysis solution. Perit Dial Int 2009; 29:647–55.
22. Kim S, Oh KH, Oh J, Kim SJ, Chung W, Song YR, et al. Biocompatible peritoneal dialysis solution preserves residual renal function. Am J Nephrol 2012; 36:305–16.
23. Lui SL, Yung S, Yim A, Wong KM, Tong KL, Wong KS, et al. A combination of biocompatible peritoneal dialysis solutions and residual renal function, peritoneal transport, and inflammation markers: a randomized clinical trial. Am J Kidney Dis 2012; 60:966–75.
24. Lai KN, Lam MF, Leung JC, Chan LY, Lam CW, Chan IH, et al. A study of the clinical and biochemical profile of peritoneal dialysis fluid low in glucose degradation products. Perit Dial Int 2012; 32:280–91.
25. Pecoits-Filho R, Heimbürger O, Bárány P, Suliman M, Fehrman-Ekholm I, Lindholm B, et al. Associations between circulating inflammatory markers and residual renal function in CRF patients. Am J Kidney Dis 2003; 41:1212–18.
26. Wang AY, Lam CW, Chan IH, Wang M, Lui SF, Sanderson JE. Long-term mortality and cardiovascular risk stratification of peritoneal dialysis patients using a combination of inflammation and calcification markers. Nephrol Dial Transplant 2009; 24:3826–33.
27. Little J, Phillips L, Russell L, Griffiths A, Russell GI, Davies SJ. Longitudinal lipid profiles on CAPD: their relationship to weight gain, comorbidity, and dialysis factors. J Am Soc Nephrol 1998; 9:1931–9.
28. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011; 377:2181–92.
29. Picotte M, Campbell CG, Thorland WG. Day-to-day variation in plasma interleukin-6 concentrations in older adults. Cytokine 2009; 47:162–5.